Short answer
Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Editas Medicine reported financial results for the quarter ended September 30, 2026.
Editas Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Editas Medicine reported financial results for the quarter ended September 30, 2026
- Business highlights accompany the quarterly results in Exhibit 99.1
- Investor-relevant figures and guidance require review of the referenced press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 1/2 Strive study approved in Australia, with EDIT-401 dosing expected in 2026 and initial safety data targeted for Q1 2027
- EDIT-401 preclinical LDL-C reduction of ≥90% maintained over 10 months, supporting potential durability but not yet demonstrating human efficacy
- BMS-986527 second IND/CTA acceptance triggered a milestone payment, increasing collaboration revenue to $10.4 million from $7.5 million
- Cash, cash equivalents and marketable securities $190.2 million, supporting operations into the second half of 2028
- Net loss narrowed to $23.4 million, or $0.15 per share, from $25.1 million, or $0.28 per share, despite higher R&D and G&A expenses
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Editas Medicine, Inc. 8-K filings
Get the next EDIT 8-K as it lands
Follow EDIT for push alerts, or ask the research agent what this filing means.